Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980883 | 0.86 | DDB1 (0.47) | NAMPTDDB1CRBNGPR119KDM4E | |
| SCHEMBL14591408 | 0.86 | DDB1 (0.47) | NAMPTDDB1CRBNGPR119KDM4E | |
| SCHEMBL29586774 | 0.84 | DDB1 (0.56) | NAMPTDDB1CRBNMAPTTHRB | |
| SCHEMBL21326156 | 0.84 | DDB1 (0.56) | NAMPTDDB1CRBNMAPTTHRB | |
| SCHEMBL14591370 | 0.82 | RECQL (0.45) | NAMPTDDB1CRBNGPR119KDM1A | |
| SCHEMBL16135233 | 0.82 | DDB1 (0.54) | NAMPTDDB1CRBNGPR119KDM4E | |
| SCHEMBL23980881 | 0.81 | LMNA (0.51) | NAMPTDDB1CRBNGPR119MAPT | |
| SCHEMBL26100307 | 0.81 | MAPK1 (0.50) | NAMPTDDB1CRBNGPR119KDM4E | |
| SCHEMBL19358133 | 0.81 | DDB1 (0.61) | NAMPTDDB1CRBNGPR119KDM4E | |
| SCHEMBL3436365 | 0.80 | GPR119 (0.58) | NAMPTGPR119KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873464-B1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3873464-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, TPH1 | NAMPT 147/4885DDB1 2694/4885CRBN 3925/4885 |
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | NAMPT 102/4885DDB1 2990/4885CRBN 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.